Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726668 | 1.00 | HSP90AA1 (0.34) | HSP90AA1NNMTSMN1; SMN2SIRT6PLAU | |
| SCHEMBL13368486 | 0.77 | POLB (0.39) | SMN1; SMN2 | |
| SCHEMBL25429065 | 0.77 | SIRT6 (0.59) | SIRT6PLAU | |
| SCHEMBL2220140 | 0.73 | SIRT6 (0.59) | NNMTSMN1; SMN2SIRT6PLAU | |
| SCHEMBL14993380 | 0.72 | ADRA2A (0.47) | — | |
| SCHEMBL1483912 | 0.72 | ADRA2A (0.47) | — | |
| SCHEMBL16834188 | 0.72 | SIRT6 (0.62) | NNMTSMN1; SMN2SIRT6 | |
| SCHEMBL17394909 | 0.72 | NNMT (0.40) | NNMTSIRT6 | |
| SCHEMBL17394908 | 0.72 | NNMT (0.40) | NNMTSIRT6 | |
| SCHEMBL30995297 | 0.72 | NPSR1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670193-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2017-06-06 | — | — | US | disclosed |
| CN-103998446-B | New trifluoromethyl oxadiazole derivative and their application in treatment disease | NOVARTIS AG (CH) | 2016-11-30 | — | — | CN | disclosed |
| EP-2785713-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-20140329825-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
| EP-2785713-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| WO-2013080120-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| EP-2403849-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | Merck Serono S.A. (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO SA (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | HSP90AA1 4598/4885NNMT 3153/4885SMN1; SMN2 1120/4885 |
| US-20140329825-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | HDAC4, HDAC5, HDAC6 | HSP90AA1 1215/4885NNMT 438/4885SMN1; SMN2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.